Triad Isotopes Closes Acquisition of Covidien’s U.S. Network of Mallinckrodt Radiopharmacies

For Immediate Release:
Triad Isotopes Closes Acquisition of Covidien’s U.S. Network of Mallinckrodt Radiopharmacies
 
Orlando, Florida.  June 1, 2010 – Triad Isotopes, Inc., headquartered in Orlando, Florida, announced
today that it closed the previously announced acquisition of the U.S. radiopharmacy network owned and
operated by Covidien, a leading global healthcare products company based in Dublin, Ireland.  This
transaction continues Triad Isotopes’ aggressive growth and investment in the radiopharmaceutical
industry.
 
Under the terms of the agreement, Triad has acquired the 37 Mallinckrodt radiopharmacies located in the
United States, with net sales of approximately $180 million in fiscal 2009. With this acquisition, Triad
becomes the second largest radiopharmacy network in the United States with over $300 million in annual
revenue, strengthening a national footprint and adding facilities located in 24 of the top 30 metropolitan
areas in the United States.  
 
 “We are pleased to welcome the Mallinckrodt network of radiopharmacies and new team members to
Triad. This transaction is the next logical step in our evolution allowing us to better serve our customers
and build value for our shareholders while making a positive impact in the communities we serve,” said
Dom Meffe, President & CEO of Triad.
 
As a result of the transaction, within 12 months Triad will increase the size of its total staff, from
approximately 800 employees to over 1,000, including doubling the size of its downtown home office as
corporate support services are added to Orlando.   
 
Triad Isotopes, Inc. owns and operates 63 radiopharmacies and 6 cyclotron facilities located nationwide.  
A radiopharmacy, also known as a nuclear pharmacy, is a pharmacy that compounds and distributes
radiopharmaceuticals used primarily in imaging procedures for cardiac and cancer diagnosis.  Cyclotrons
are utilized to produce FDG (Fluorodeoxyglucose), a short-lived positron-emitting isotope suitable for
PET (Positron Emission Tomography), an imaging technology that can be used to assess tissue
biochemistry.    
 
The Triad business model provides customers flexible and creative solutions, choice of product through
an open formulary and quick decision making at the local level. The Triad team is our customers’ trusted
advisor by supporting their clinical and operational needs while living in and improving the communities
they serve. For more information, visit www.triadisotopes.com.